The Virus Reduction Therapy Study Group: T. Ide, H. Nishida, Kurume University School of Medicine; H. Yokoyama, T. Yamashita, Kanazawa University Graduate School of Medicine; H. Moriwaki, M. Nagaki, Gifu University School of Medicine; J. Sugihara, H. Takahashi, Gifu Municipal Hospital; T. Ishikawa, M. Miyata, K. Nishikawa, Aichi Medical University; S. Nagoshi, S. Sugahara, Saitama Medical University; K. Yamamoto, T. Mizuta, T. Ando, Saga Medical School; Y. Takei, N. Enomoto, H. Tsuda, Juntendo University School of Medicine; Y. Sumino, K. Ishii, Toho University School of Medicine; H. Saisho, O. Yokosuka, Chiba University Graduate School of Medicine; K. Eguchi, K. Hamasaki, Graduate School of Biomedical Sciences, Nagasaki University; K. Sawada, K. Fukunaga, Hyogo College of Medicine; Y. Arakawa, M. Moriyama, Nihon University School of Medicine; M. Imawari, T. Ito, Showa University School of Medicine.
Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load
Article first published online: 15 JUN 2007
Volume 37, Issue 9, pages 701–710, September 2007
How to Cite
Fujiwara, K., Kaneko, S., Kakumu, S., Sata, M., Hige, S., Tomita, E., Mochida, S. and The Virus Reduction Therapy Study Group (2007), Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatology Research, 37: 701–710. doi: 10.1111/j.1872-034X.2007.00117.x
- Issue published online: 15 JUN 2007
- Article first published online: 15 JUN 2007
- Received 25 January 2007; revision 22 February 2007; accepted 2 March 2007.
- combination therapy;
- double filtration plasmapheresis;
- early viral reduction;
- sustained virus response
Aim: The efficacy and safety of double filtration plasmapheresis (DFPP) plus interferon (IFN) combination therapy were compared with those of IFN therapy alone in 193 chronic hepatitis C patients having a high hepatitis C virus ribonucleic acid load of difficult-to-treat genotype 1b.
Methods: All patients received either interferon alpha-2b (IFN-α-2b) monotherapy or combination therapies with ribavirin and IFN-α-2b or pegylated interferon alpha-2b (PEG-IFN-α-2b). Each patient individually decided whether to receive concomitant DFPP. DFPP was immediately followed by IFN treatment, and up to five sessions were given during the first week.
Results: Sixty patients decided to receive DFPP. In the DFPP plus PEG-IFN-α-2b therapy group (n = 30), viral load reduction at 4 weeks after the start of treatment was greater than innon-DFPP (n = 74) (2.47 vs 1.52, log, P = 0.010), and the sustained virus response was also higher (77.8% vs 50.0%), even in cases of re-treated patients (relapsers or non-responders to previous IFN therapies). Adverse events, mild and transient, were observed in 38.3% of all DFPP-treated patients.
Conclusion: DFPP plus IFN combination therapy produced a great reduction of viral load during the early stage of treatment and achieved a high sustained virus response, suggesting that this combination therapy may be a new modality for chronic hepatitis C patients at difficult-to-treat states.